New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:06 EDTGEVASynageva issued U.S. patent for treatment of LAL deficiency
Synageva BioPharma announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,663,631 covering methods of treating lysosomal acid lipase deficiency. This patent provides protection until 2031, not including any patent term extension. The patent complements Synageva’s existing and planned global patent portfolio covering its LAL Deficiency program, which includes intellectual property directed to composition of matter, methods of use, and manufacturing.
News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
10:00 EDTGEVAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:28 EDTGEVASynageva downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
February 26, 2015
16:48 EDTGEVASynageva sees FY15 operating expenses $280M-$25M
Subscribe for More Information
16:48 EDTGEVASynageva reports Q4 EPS ($1.73), consensus ($1.71)
Subscribe for More Information
February 23, 2015
08:09 EDTGEVASynageva announces FDA accepts accepts BLA filing for Kanuma
Subscribe for More Information
07:22 EDTGEVASunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use